Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1115
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1104 to $1115.
March 13, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Regeneron Pharmaceuticals and increased the price target from $1104 to $1115.
The increase in price target by a reputable analyst like Morgan Stanley suggests a strong confidence in Regeneron Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to a short-term increase in REGN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100